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Abstract
More than 450 million people worldwide have diabetes mellitus (DM), a 
metabolic disorder characterized by an increase in blood glucose level (hyper-
glycemia) that arises from insufficient insulin secretion or resistance to insulin’s 
action. More than 70% of individuals with chronic DM will develop cardiovascular 
diseases (CVDs) including atherosclerosis and coronary artery diseases (CADs), 
hypertension, cardiac arrhythmias, cardiomyopathy (heart failure), stroke, and 
chronic kidney disease. A significant number of these individuals will also suc-
cumb to sudden cardiac death (SCD). SCD usually occurs in early morning from 
abnormal heart rhythms or arrhythmias and ventricular fibrillation. When the 
pumping action of the heart becomes erratic, a reduction in oxygenated blood 
to the brain leads to unconsciousness and brain damage. SCD is independent of 
age and sex and positively correlates with impairment in cardiac metabolism, 
muscle damage, fibrosis, apoptosis, hypertrophy, ischemia, and deranged cation 
signaling. This review centers on mechanisms by which intracellular cations (Na+, 
K+, and Ca2+) handling, inflammation, and oxidative and carbonyl stresses due 
to diabetes-induced hyperglycemia can lead to the deterioration of excitation/
contraction coupling (ECC), impaired contractility, arrhythmias, and SCD in DM 
patients. It also discusses the beneficial effects of exercise training to attenuate the 
risk of SCD.
Keywords: arrhythmias, cardiomyopathy, diabetes, exercise, heart,  
hyperglycemia, patients, sudden cardiac death
1. Introduction
Sudden cardiac death (SCD) remains a major global public health problem, 
especially in developed countries such as the United States of America (USA), 
United Kingdom (UK), Germany and other countries. Moreover, SCD is also the 
most common cause of death worldwide, accounting for >50% of all cardiovascular 
disease (CVD)-related deaths. SCD is characterized by unexpected loss of the 
Sudden Cardiac Death
2
pumping action of the heart due to a disturbance in its electrical system that results 
in irregular and dangerously fast beating of the heart [1]. The ventricles may flutter 
or quiver (ventricular fibrillation), disrupting the pumping action of the myocar-
dium, thereby stopping blood flow to the body. The blood flow to the brain is a 
matter of grave concern for the patients since reduced oxygenated blood supply to 
the brain can lead to unconsciousness and permanent damage to the brain. As such, 
death can follow unless the patient receives emergency treatment [2, 3]. Therefore, 
time is extremely critical when someone or a clinician is helping an unconscious 
person whose heart is not pumping (no pulse). SCD represents a major challenge 
for the clinician especially in individuals without a previous history of cardiac 
diseases. Early prediction of individuals at risk of SCD can be life-saving. Currently, 
most individuals experiencing SCD may not be identified as being a high risk and as 
such, the patients do not have ready access to a defibrillator. As a result, there must 
be community-based public access to defibrillation programmes in order to save the 
lives of the potential victims. SCD seems to occur most frequently in adults in their 
mid-30s to mid-40s and during working age, affecting both men and women. With 
SCD, some patients experience tachycardia, dizziness and fainting while in some 
cases there are no prior symptoms [4, 5].
2. Risk factors
The two major risk factors are previous myocardial infarction and coronary artery 
disease (CAD). However, there are other risk factors which include age, gender (pre-
dominant in males), ethnicity, reduced ejection fraction, a previous sudden cardiac 
arrest, familial predisposition to SCD, bradycardia, ventricular fibrillation, heart 
defects at birth, coronary artery abnormalities due to atherosclerosis, dilated cardiomy-
opathy, hypertrophic cardiomyopathy, significant changes in blood levels of potassium 
and magnesium, obesity, diabetes, recreational drug abuse and taking drugs that are 
“pro-arrhythmic” which may increase the risk for life-threatening arrhythmias [4].
3. Management of SCD
In order to prevent SCD, it is imperative to impose an aggressive management of 
cardiovascular risk factors at all levels including schools, universities, clinics, work-
place and others. These include performing moderate exercise regularly, educating 
patients about the dangers of CVDs, promoting a healthy diet, restricting stress, 
reducing consumption of sugar, saturated fat and salt and stop smoking to promote 
a heart healthy behavior to all, particularly in young children and adolescents.
Finally, a preclinical prediction of patients at risk of SCD and early detection 
of the disease is crucial for early intervention and definitely these will reduce the 
incidence of SCD dramatically [4, 5]. Screening of family members who are suscep-
tible to arrhythmias and SCD can help with early diagnosis and also and managing 
the arrhythmias [6].
4. Epidemiology of diabetes-induced sudden cardiac death
SCD is responsible for more than 100,000 deaths annually in the UK and 
400,000 in the USA, far more than cancer and other individual non-communicable 
disease. It is estimated that 27,000 patients in the UK and 80,000 patients in the 
USA die annually from diabetes-induced SCD. Globally, SCD is responsible for half 
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of all deaths due to heart disease [7]. Most cases of SCD are related to undetected 
cardiovascular diseases. SCD are directly linked to DM and CVDs are responsible 
for over 80% of the mortality in the diabetic population [8]. Epidemiological 
data show that macro-vascular complications including coronary artery disease 
(CAD), peripheral vascular disease (PVD) and SCD are 2–4 times more common 
among diabetic patients when compared with nondiabetic people [9]. According 
to the Framingham study, the frequency of CAD is twice more common in diabetic 
patients of both sexes than nondiabetic individuals [10]. This review will now focus 
on the mechanisms of diabetes-induced SCD, but first it is of paramount impor-
tance to understand the structure and function of the heart.
5. Anatomy and physiology of the heart
The mammalian heart is a four-chambered muscular organ, which is located 
in the anterior mediastinum, posterior to the sternum and encapsulated by the 
pericardium. The pumping action of the heart is central to the functioning of the 
circulatory system. The CVS composed of the blood, the heart and blood vessels 
[11]. The heart is a strong muscular organ, which continues to pump blood to dif-
ferent parts of the body throughout our lives. It beats continuously using up a vast 
amount of energy daily [12]. The structure of the heart is depicted in Figure 1 and it 
is composed mainly of three layers of muscles, namely the epicardium or the exter-
nal layer, the middle layer or myocardium and the inner most layer or endocardium. 
Damage to these muscles and other conduction tissues in the heart due to diabetes 
and other diseases is responsible for SCD.
The larger and strong muscular tissue of the myocardium is responsible for 
ventricular contraction, and it is also divided into left and right sides by a septal 
wall. Each side of the heart is made up of two chambers consisting of the upper atria 
and the lower ventricles [12]. The left side of the heart pumps oxygen-rich blood 
to the different parts of the body via the aortic valve to the aorta (systemic circula-
tion), while the right side delivers blood to lungs via the pulmonary valve and the 
pulmonary artery for oxygen replenishment in the lungs (pulmonary circulation). 
The heart has four valves which allow for unidirectional flow of blood thereby 
Figure 1. 
The mammalian heart. Components are described in the text (image courtesy www.beyondbiology.org).
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preventing backflow. In turn, the right atrium receives retuning deoxygenated 
blood from the body through the superior and inferior vena cavae, while the left 
atrium receives oxygenated blood from the lungs through pulmonary vein. The 
heart itself needs a good supply of blood via the coronary arteries. These include 
the left anterior descending coronary artery, the left circumflex artery and the right 
coronary artery supplying the myocardium with oxygen-rich blood. The apex of the 
heart is the pointed end and the other end is called the base of the heart [13].
The orderly events that take place during the cardiac cycle are controlled by 
the electrical conduction system of the heart (Figure 2). An impulse is initiated 
at the sinoatrial node (SA-node) and then passes on to the atrioventricular node 
(AV-node) via conducting fibers via the atria. From the AV node, the impulse is 
conducted throughout the ventricles via the Purkinje fibers resulting in depolariza-
tion of the heart. Damage to the conducting tissues can result in sudden arrhyth-
mias and possible SCD. Blood is pumped by the right ventricle into the pulmonary 
circulation at a lower pressure than blood pumped by the left ventricle into the 
systemic circulation. It follows that the haemodynamic stresses in the right and left 
side of the heart are very different. Even within the ventricles, the electro-mechani-
cal properties of ventricular cardiac myocytes vary trans-murally [14].
6.  SCD due to diabetes-induced autonomic system neuropathy and 
brady-arrhythmias
The heart is innervated by the nerves of the autonomic nervous system (ANS) 
[15]. The ANS consists of sympathetic and parasympathetic nerves which innervate 
the heart. The parasympathetic or vagus nerve originates from the inhibitory center 
in medulla of the brainstem. The vagal nerve innervates mainly the atria (sinoatrial 
node) and the atrio-ventricular node (see Figure 2). Upon stimulation, it releases 
the neurotransmitter, acetylcholine (ACh). The main function of ACh is to activate 
cholinergic muscarinic receptors in the heart muscles leading to reductions in 
Figure 2. 
Diagram showing the electrical system of the mammalian heart with the conducting tissues including the 
SA node, AV node and Purkinje fiber network. SCD is usually caused by abnormal heart rhythms called 
arrhythmias and the most common life-threatening arrhythmia is ventricular fibrillation, which is an erratic, 
disorganized firing of impulses from the ventricles (see lower chambers with Purkinje network of fibers). When 
this occurs, the heart is unable to pump blood, and death will occur within minutes, if left untreated (image 
courtesy www.beyondbiology.org).
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conduction of impulse (negative dromotropic effect), rate (negative chronotropic 
effect), contraction (negative inotropic effect) and metabolism of the myocardium. 
On the other hand, the sympathetic nerve originates from the thoracic region of 
the spinal cord and it innervates the whole heart. It releases the neurotransmitter 
noradrenaline (norepinephrine) (NA) which activates beta-1–adrenergic receptors 
in the heart leading to increases in conduction of impulse (positive dromotropic 
effect), rate (positive chronotropic effect), contraction (positive inotropic effect) 
and enhanced metabolism of the myocardium. The two nerves of the ANS work in 
tandem to maintain the neural homeostasis of the heart [16].
Figure 3 illustrates the relationship between diabetes-induced cardiac auto-
nomic system neuropathy and brady-arrhythmias in SCD. In diabetes-induced 
cardiac autonomic neuropathy, the sympathetic nerve to the heart is damaged and 
its activity is reduced leading to slowing of the heart or brady-arrhythmias, heart 
rhythm disturbances and even SCD. Moreover, diabetes can also downregulate 
the beta-adrenergic receptor in the myocardium which in turn synergizes the 
brady-arrhythmias leading to cessation of the heart or SCD. There is new evidence 
that diabetes-induced cardiomyopathy is common and there is an increased risk 
of arrhythmias as a result of dysfunction of the cardiac conduction system (CCS) 
[17, 18]. This is due mainly to hyperglycemia-induced fibrosis which results in 
Figure 3. 
Flow diagram showing the cellular and molecular events in the myocardium due to diabetes-induced 
hyperglycemia culminating in Brady-arrhythmias and subsequently SCD. ROS = reactive oxygen species; 
MGO = methylglyoxal, a reactive carbonyl species.
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dysfunction of the CCS in the diabetic heart (see Figure 2). Moreover, it was 
demonstrated by Zhang et al. [18] that diabetes-induced fibrosis of the heart 
was associated with the reduction of potassium channel (HCN4), Cav1.3, Cav3.1 
(calcium channel), NCX1, (sodium-calcium exchanger) and connexin (Cx45) 
protein expression in the sinoatrial node of the heart which in turn resulted in 
brady-arrhythmia and possibly SCD [18]. Moreover, reduced ryanodine (RyR2) 
and sodium-calcium exchanger (NCX1) protein expression in the atrio-ventricular 
junction of the heart (AVJ) is believed to contribute in part to the prolongation 
of the PR interval. Similarly, reduced protein expressions of RyR2, NCX1, Cx40, 
Cx43, and Cx45 in the Purkinje fibers (PFs) are responsible for the prolongation of 
QRS complex. The downregulation of neuro-filament M sub-unit (NF-M) and β1-
adrenergic receptor could also be linked to the reduced autonomic nervous control 
of the heart [17, 18]. All these cellular and molecular processes subsequently result 
in cardiac arrhythmias, QT interval prolongation and SCD of diabetic patients [19].
7. Cardiac muscle
In order to appreciate how diabetes-induced hyperglycemia is inducing fibrosis 
and cardiomyopathy, it is paramount importance to understand first, the structure 
of the cardiac cell or cardiomyocyte. Cardiac muscle, at the microscopic level, can 
be described as a composite tissue. It is made of various cell types, mainly myocytes 
and fibroblasts which are supported by extracellular matrix (ECM), all of which are 
permeated by fluids [15]. The myocardial ECM is made of macro-molecules which 
are produced by local fibroblasts. They consist of a fibrillar collagen network, a 
basement membrane and proteoglycans [20]. The function of the fibrillar collagen 
network is to strengthen the matrix, thereby giving strong structural support of 
the adjoining cardiomyocytes and the means by which they shorten to exert their 
contractile effect efficiently during ventricular pump action and thus, contributes to 
myocardial diastolic stiffness [21]. The heart is composed of different types of colla-
gens including fibrillar collagen type I with the tensile strength of steel and fibrillary 
collagen type III which is the most abundant phenotypes [21]. Secondly, the base-
ment membrane which surrounds the myocyte is attached to the sarcolemma and 
to the fibrillar collagen network. The myocyte adherence to basement membrane is 
a major determinant in maintaining cell shape and positional integrity within the 
ventricular wall [22]. Thirdly, the proteoglycans are composed of a protein core to 
which polysaccharide chains called glycosaminoglycans are covalently bound. These 
negatively charged molecules possess significant osmotic activity helping to trap 
and to store growth factors within ECM. Proteoglycan molecules in the connective 
tissue form a highly hydrated, gel-like “ground substance” in which the fibrous 
proteins are embedded. [22, 23]. The function of the polysaccharide gel is to prevent 
any compressive forces on the matrix thereby allowing the rapid diffusion of nutri-
ents, metabolites and hormones between the blood and the cardiac tissue cell [23].
8. Sudden cardiac death due to diabetes-induced cardiomyopathy
Figure 4 illustrates the various pathways and events leading to diabetes-induced 
cardiomyopathy, arrhythmias and SCD due to the diabetes-induced hyperglycemia. 
These pathways include structural changes to cardiac muscles as well as apoptosis, 
altered calcium handling, insulin resistance in the heart, increased lipid uptake 
into the heart, glucotoxicity, metabolic disturbances, fibrosis, hypertrophy and the 
renin-angiotensin-aldosterone system (RAAS). DM can also affect cardiac structure 
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and function without causing changes in either high blood pressure (HBP) or CAD 
resulting in a debilitating condition called diabetic cardiomyopathy (DC) [24]. 
This term was first described by cardiac clinicians in 1972 after the examination of 
patients with DM and HF but without the appearance of HBP or CAD [25]. It is now 
well established that DC is responsible for mortality and morbidity among diabetics 
[26]. DC generally refers to the dysfunction of the left ventricle due to an enlarged 
weak heart in diabetic patients independent of CAD or HBP. The onset of DC is 
triggered by the diabetes–induced hyperglycemia leading to the production of a 
number of insults in the myocardium including TGF-beta 1, reactive oxygen species 
and reactive carbonyl species which in turn induce cellular structural damage to the 
heart. As a consequence, the initial effect is diastolic dysfunction in which the heart 
is unable to relax properly due to a derangement in cellular calcium homeostasis or 
elevated diastolic calcium due to impairment in cellular calcium regulatory trans-
porting proteins in the myocardium. Following this, systolic dysfunction develops 
in which the heart is unable to pump blood efficiently to meet the demand of the 
body or heart failure. The final effect over time is arrhythmias and subsequently 
SCD. The most common contributors to DC onset and progression are left ventricu-
lar hypertrophy, metabolic abnormalities, extracellular matrix changes, small vessel 
disease, cardiac autonomic neuropathy, insulin resistance, oxidative stress and 
apoptosis, all leading to cardiac remodeling [27].
As DC was first reported in 1972, considerable data on its pathogenesis and 
clinical feature have been collected. DC affects the heart by enhancing fatty acid 
metabolism, suppresses glucose oxidation and modifies intracellular signaling, 
all of which lead to alteration in multiple steps of excitation-contraction coupling 
process, inefficient energy production, increased susceptibility to ischemia and 
contractile dysfunction [28, 29].
DM leads to structural and functional changes in the heart. The structural 
changes are manifested by left ventricular muscle disarray and hypertrophy, 
interstitial fibrosis, increased cell death (apoptosis) and oxidative stress, all of 
which result in diastolic and systolic dysfunctions as well as impaired contractile 
reserve [30]. In DM, the mass of the left ventricle is an independent marker for 
Figure 4. 
Flow diagram showing the relationship between obesity and other risk factors-induced diabetes and sudden 
cardiac death (SCD) in the myocardium. Diabetes-induced hyperglycemia elicits structural, functional, 
and biochemical changes via different cellular pathways in the heart leading to diabetic cardiomyopathy, 
arrhythmias, and sudden cardiac death (SCD).
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SDC, and it often occurs independent of blood pressure in the atria. As such, DM is 
an independent risk factor which is responsible for enlargement of the left ventricle 
and generally stiffness of the heart [31].
It is particularly noteworthy that at cellular electrical level in the diabetic 
heart, the cardiac action potential duration (CAP) is consistently prolonged due 
to elevated intracellular calcium which is essential for the myocardium contrac-
tion [32]. It is now evident that DC-induced abnormalities during cardiac muscle 
contractility correlate closely with alterations in intracellular free Ca2+concentration 
[Ca2+]i. It was previously reported that diabetic cardiac dysfunction arises as a result 
of changes in the expression and/or activity of transporting proteins that regulate 
Ca2+ during the cardiac cycle [33]. Thus, DC results in changes in biomechanical, 
contractile, and hypertrophic properties of the cardiac myocytes leading subse-
quently to arrhythmias and SCD.
9. Metabolic disturbances and sudden cardiac death
Metabolic disturbances such as altered lipid handling and substrate utilization, 
decreased mechanical efficiency, mitochondrial dysfunction, disturbances in non 
oxidative glucose pathways and increased oxidative stress are all hallmarks of DM 
[34]. Chronic hyperglycemia leads to non-enzymatic glycation of vascular and 
membrane proteins, producing advanced glycation end products (AGEs) and reac-
tive oxygen species (ROS) and reactive carbonyl species (RCS) [35]. One major RCS 
is methylglyoxal (MGO) which is generated during glycolysis and the breakdown of 
lipids and glucose. In a previous study, it was reported that diabetes was associated 
with a large amount of collagen deposition around blood vessel and between the 
myofibers of heart biopsies taken from patients. Moreover, lipofuscins which are 
brown pigment granules that composed of lipid-containing residues were found to 
be deposited in left ventricular transmural biopsies. Similarly, myocardial triglycer-
ide and cholesterol were also reported in these biopsies in large amount [36].
Insulin has a vital role to play in the regulation of cardiac metabolism and function 
[37]. Alterations of myocardial substrate and energy metabolism are considered as 
significant factors for the development of DC [38]. DM is characterized by reduced 
glucose and lactate metabolism and increased fatty acid (FA) metabolism [39]. In 
1988, the glucose transporter GLUT family was discovered [40] and later, it was 
reported that glucose transport in the myocardium was impaired during diabetes 
because of decreased expression of GLUT1 and GLUT4 proteins and mRNA levels 
[41]. Likewise, glucose oxidation is reduced via the inhibitory effect of FA oxidation 
on pyruvate dehydrogenase complex due to high circulating FFA [42]. Insulin exerts 
its effect on glucose uptake in heart muscles by binding to insulin tyrosine kinase 
receptor (ITKR) via auto-transphosphorylation. In turn, this process initiates a 
signaling cascade mechanism which is accompanied by phosphorylation of phospha-
tidyl-inositol-3 kinase (PI3K), phosphoinositide-dependent kinase 1 (PDK1), Akt 
and protein kinase C (PKC). All these events allow for the translocation of GLUT1 
and GLUT4 to the membrane facilitating glucose uptake into cardiac muscle cell. 
Contraction-evoked GLUT4 translocation represents the major mechanism that regu-
lates glucose uptake by the myocardium heart, with only a small role by GLUT1 [43].
Both insulin resistance (IR) and hyperinsulinemia are risk factors for DC [44]. 
They seem to disturb insulin-induced glucose metabolism thereby significantly 
worsen the metabolic efficiency in cardiac and skeletal muscles. Insulin exerts its 
insulting effect in the diabetic heart via two processes involving the abnormalities 
of systemic metabolism and insulin signaling pathways, both of which are intrinsic 
to the cardiac tissue [45]. In the evolution of IR, the initial change that develops in 
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the hearts of animal models is the impairment in the ability of insulin to increase 
glucose transport [46]. IR is also associated with cardiac contractile dysfunction 
and SCD [47]. Moreover, IR is associated with metabolic alteration and the develop-
ment of DC [45]. Circulating FAs and triglyceride (TG) are increased by enhanced 
lipolysis in adipose tissue and lipoprotein synthesis in liver as a result of hyper-
glycemia and IR. It is now known that the FAs are converted to a lipid- like TG or 
ceramide when the FAs exceed the oxidative capacity of the heart leading to lipotox-
icity and cell apoptosis [48]. As a result, DM subsequently leads to an increase in the 
rate of FA oxidation which is accompanied by a concurrent decrease in the rate of 
glucose oxidation.
10. Relationship between fibrosis and sudden cardiac death
Diabetes is well known to induce severe structural changes in the heart including 
replacement of apoptotic myocytes with fibrotic tissue and myocyte enlargement 
and disarray. These changes can affect electrical and mechanical activities of the 
heart [47]. Fibrosis can result in stiffness of the heart, remodeling, conduction 
abnormalities, arrhythmias and even SCD [12, 13, 17, 18]. Moreover, increased 
interstitial deposits of collagen filaments leading to fibrosis can act as insulating 
barriers, promoting not only impulse conduction slowing, but also conduction 
block [17, 18]. Recent experimental findings in isolated whole-heart studies indicate 
that fibrosis may also modulate the formation and propagation of cardiac-after 
potentials which can trigger electrical activity of the heart resulting in ventricular 
tachycardia and ventricular fibrillation (VT/VF). Since the infiltration of the myo-
cardium with fibrosis can induce cardiovascular events as well as impairing cardiac 
diastolic and systolic function, it is now possible to assess the extent of myocardial 
fibrosis using cardiac magnetic resonance (CMR). CMR is of paramount impor-
tance as a prognostic tool in determining the different types of cardiomyopathies, 
especially when it is combined with myocardial T1 mapping [49].
In addition, the replacement of myocytes with fibrotic tissue can reduce the 
number of force generating sarcomeres leading to a reduction in contractile func-
tion and subsequently arrhythmias and SCD [50]. Interstitial and perivascular 
fibrosis is a histological symptom of DC [25] and the extent of fibrosis correlates 
closely with the weight of the myocardium. The pathogenesis of fibrosis in the 
diabetic heart is proposed to be due to diabetic micro-angiopathy. When the 
diabetic heart is affected by either hypertension or CAD, there may be addi-
tive micro-angiopathy and large vessel-induced ischemia, all leading to diffuse 
myocardial scarring. Generalized fibrosis can result in increased wall stiffness 
and diastolic dysfunction [18, 51]. It is now well recognized that activation of the 
renin-angiotensin system (RAS) has an important biochemical role to play in the 
development of DC [42]. In diabetic heart, Angiotensin II (AngII) receptor density 
and mRNA expression are elevated [52]. It has been reported that DM can enhance 
the activation of RAS resulting in an increase in oxidative damage, fibrosis and cell 
apoptosis [53].
In contrast, the inhibition of the RAS can lead to a reduction in reactive oxygen 
species (ROS) level, similar to the effect observed with antioxidant treatment in 
streptozotocin-induced diabetic rat model [54]. One example of an ROS generat-
ing endogenous molecule is the RCS, methylglyoxal (MGO). Its accumulation 
to toxic levels during diabetes is due to a decrease in the activity of the enzyme 
(glyoxylase-1), the primary enzyme responsible for degrading MGO [55]. AngII, 
given exogenously to rodents, has been shown to cause cellular changes within the 
myocardium leading to hypertrophy and fibrosis and even SCD [56].
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Mitochondria are the powerhouse of cells, and they play a major role in energy 
production. They are also involved with a number of cellular processes includ-
ing homeostasis, free radical production and cell death [57]. Mitochondria exert 
marked biochemical effect on FA and glucose metabolism. However, diabetes 
can induce mitochondrial dysfunction leading to impaired cellular metabolism. 
A previous study reported ultrastructural and functional changes, as well as 
protein composition, in cardiac muscle mitochondria following diabetes [58]. In 
streptozotocin-induced type 1 diabetic mice, impaired function and ultrastructure 
abnormalities of cardiac muscles were associated with damage to the mitochon-
dria. The impairment of the mitochondria was accompanied by increases in 11 
specific mitochondrial proteins. These include an elevation of mRNA for the 
mitochondrial regulatory protein and increased total mitochondrial DNA area as 
well as number. These findings clearly indicate that the mitochondria are the major 
targets of diabetes-induced damage to the heart [59]. Moreover, a recent study has 
shown a reduction of ATP production by the mitochondria following diabetes. 
Another study [60] examined the relationship between impaired insulin signaling 
and altered mitochondrial energetics in a mouse model of type 1 diabetes with a 
cardiac-specific deletion of the insulin receptor. The results reveal impaired insulin 
signaling in the heart and this in turn promotes oxidative stress and mitochondrial 
uncoupling. These processes were associated with reduced fatty acid oxidative 
capacity and impaired mitochondrial energetics [61]. It is now well established 
that mitochondria from the diabetic heart can produce more reactive oxygen spe-
cies (ROS) and reactive carbonyl species (RCS) than normal mitochondria [62]. 
According to the molecular theory of DC, hyperglycemia (HG) is the main patho-
genic factor or insult resulting in arrhythmias and SCD [60].
11. Obesity and sudden cardiac death
DC is also accompanied by other comorbidities such as obesity and hyperten-
sion and these two complications often precede the development of fibrosis, 
apoptosis, hypertrophy, remodeling of the myocardium, diastolic and systolic 
dysfunctions, CAD, arrhythmias and SCD [63]. SCD in the young obese popula-
tion normally happens in individuals without a known cardiac history [64]. More 
recently, chronic obese patients have been reported to be more susceptible to 
increased risk of SCD. As such, this is becoming a major concern and challenge for 
clinicians and health services globally, especially since the prevalence of obesity 
has been increasing steadily in both developed and developing countries around 
the world. Both obesity and DM share the main risk factors including inactivity, 
smoking and diets rich in sugar and fats. Most obese patients are hypertensive, 
pre-diabetic, as well as having fully blown diabetes, experiencing obstructive sleep 
apnea due to their excessive weight and metabolic syndrome. All of these patho-
logical parameters are well-known risk factors for CVDs, including SCD. It is now 
evident that structural, functional and metabolic factors modulate and influence 
the risk of SCD in the obese population [65]. Obesity exerts numerous haemody-
namic changes on the CVS such as increased cardiac output and diastolic filling 
pressures, both of which result in LV hypertrophy and dilatation. In addition, 
obesity can induce adverse electrical changes in the myocardium including prolon-
gation of the QRS and increase in QT intervals on the ECG, as well as an increase 
in QT dispersion. Moreover, the late potentials on signal averaged ECG are also 
more common in obese compared with lean individuals. These obese-induced 
adverse structural and electrical insults on the heart seem to create a substrate that 
is susceptible to SCD [66].
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Obesity-induced pathogenesis of the myocardium is associated with the produc-
tion of lipids, oxidized LDL particles and free FAs which activate the inflammatory 
process in the body and thus, trigger the development of cardiac dysfunction. 
Inflammation is responsible for the steps toward the development of atherosclero-
sis, from early endothelial cell dysfunction to the late atherosclerotic plaque forma-
tion causing complications. All these pathological processes are related to obesity, IR 
and diabetes. During diseased processes in the heart, fatty tissue releases adipocyto-
kines which in turn induce IR, endothelial cell dysfunction, hypercoagulability and 
systemic inflammation, thereby facilitating the atherosclerotic process. Likewise, 
the inflammatory adipocytokine such as TNF-α also rises to higher levels in visceral 
obesity. As a result, the heart releases an increased level of C-reactive protein (CRP) 
which is associated with an enhanced risk of ischaemia, myocardial infarction and 
peripheral vascular disease, all of which can facilitate arrhythmias and SCD [67].
12.  Impaired calcium and potassium homeostasis and sudden cardiac 
death
Calcium (Ca2+) is a major trigger, a modulator, a second messenger and a 
regulator of cardiac contractility [24, 68, 69]. It is well known that most of the Ca2+ 
that activates contraction is released from sarcoplasmic reticulum (SR) through 
ryanodine receptors (RyRs). RyRs are themselves activated by Ca2+ which enters the 
myocyte via voltage-dependent L- type Ca2+ channels and this mechanism is known 
as Ca2+-induced Ca2+ release (CICR) [68]. The cytosolic Ca2+ in turn interacts 
with cardiac contractile proteins. By binding to troponin C, the Ca2+ triggers the 
sliding of thin and thick filaments, which results in cardiac contraction. Ca2+ then 
returns to diastolic levels mainly by the uptake of Ca2+ into the SR via the SR Ca2+ 
pump (SERCA2a) and extrusion of Ca2+ from the cell via the sarcolemmal Na+-Ca2+ 
exchanger and the sarcolemma Ca2+-ATPase pump [24]. DM leads to mitochondrial 
dysfunction which contributes to the development of DC by altering ATP genera-
tion and Ca2+ mobilization [69]. A previous study has shown that diabetes-induced 
HG plays an integral role in altering the expression and function of RyRs, Na+-Ca2+ 
exchanger and SERCA. Failure of these three major calcium transporting proteins to 
function efficiently in cardiac muscles is the pivotal factor which is responsible the 
impairment of myocardial systolic and diastolic functions [30]. In such situations, 
Ca2+ homeostasis is altered during DC thereby affecting the ability of SR to take up 
Ca2+ and the Na+-Ca2+ exchanger, and the sarcolemma Ca2+ ATPase to move Ca2+ out 
of the cell leading to elevated diastolic [Ca2+]i. Second, in diabetes, channel proteins 
within RyRs undergo carbonylation leading to asynchronous release of calcium into 
the cytoplasm from the SR [57]; (see Figure 4).
Like cellular calcium, potassium homeostasis is of crucial importance for normal 
cellular function and it is regulated by ion-exchange pumps, co–transporters and 
channels. Normal plasma potassium values range between 3.8 to5.1 mmol/l [70]. 
The deviations to both extremes (hypo- and hyperkalaemia) are associated with 
increased risk of arrhythmias and SCD especially in diabetes-induced chronic 
kidney failure. Moreover, diabetic patients are at high risks when the failing kidneys 
are unable to remove potassium from the plasma and as such it builds up in the 
body leading to hyperkalaemia. Potassium levels below 3.0 mmol/l cause significant 
Q-T interval prolongation with subsequent risk of torsade des pointes, ventricular 
fibrillation and SCD. Potassium levels above 6.0 mmol/l cause peaked T waves, 
wider QRS komplexes and may result in bradycardia, asystole and SCD [70]. Tight 
regulation of serum potassium levels is necessary for many physiologic processes, 
including normal cardiac conduction and function [71].
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13. Beneficial effect of daily exercise in sudden cardiac death
The beneficial cardiac protection, following regular exercise training (ET) 
in diabetic patients, has been reported in both clinical and experimental animal 
studies. It is now known that acute endurance ET is accompanied with significant 
increase in maximum oxygen consumption and enhanced cardiac output, stroke 
volume and systolic blood pressure which are all associated with decreased periph-
eral vascular resistance. On the other hand, long-term cardiovascular adaptation 
to dynamic training results in increased maximal oxygen uptake due to increased 
cardiac output and arteriovenous oxygen difference. In contrast, strength exercise 
training induces little or no increase in oxygen uptake. Thus, endurance exercise 
predominantly produces volume load on the left ventricle (LV), and strength 
exercise causes largely a pressure load [72]. It is now well established that LV 
physiological hypertrophy due to daily endurance exercise training can result in 
a proportional increase in myocardial cell length and width without evidence of 
myocardial hyperplasia in the majority of cases. This beneficial process is mediated 
via an increase in the expression of cardiac insulin-like growth factor-1 (IGF-1) and 
a concurrent activation of phophoinositide-3 kinase (PI3K) [73].
Both physiological and pathological cardiac enlargement (hypertrophy) is 
caused by different stimuli and both are functionally distinguishable. A pathologi-
cal stimulus is normally caused by a pressure overload due to either aortic stenosis 
or hypertension producing an increase in systolic wall stress. In turn, this results 
in a concentric type of hypertrophy. This process occurs when the heart develops a 
thick wall with relatively small cavities. [74]. ET can also induce an adaptation of 
the coronary artery circulation which is divided into two main processes. Firstly, 
angiogenesis is initiated leading to an expansion of the capillary network by the 
formation of new blood vessels which occur at the level of capillaries and resistance 
arterioles, but not in large coronary arteries [75]. The cellular and subcellular 
mechanisms underlying ET-induced angiogenesis are still unknown. A number of 
studies [76–78] have demonstrated that growth factors including vascular endothe-
lial growth factor (VEGF), fibroblast growth factor (FGF) and angiopoietins (AQP) 
and their corresponding receptors are involved in the angiogenesis process. Studies 
have also shown that sprouting angiogenesis is associated with a number of pro-
teases which are relevant for the breakdown of the capillary basement membrane. 
These functional proteins include matrix metalloproteinases (MMPs), urokinase, 
tissue plasminogen activator and plasminogen [76–79]. Cardiac muscle function 
is highly dependent on an adequate coronary blood flow due to high metabolic 
demand. Thus, coronary artery dysfunction can have a direct impact on myocardial 
function. It was demonstrated that an eight-week moderate-intensity exercise 
training regime in individuals with T2DM can significantly enhance endothelial 
cell function in the brachial coronary artery. This was associated with a significant 
improved blood flow-mediated dilation [76].
It is now known that repetitive exercise training sessions can stimulate other 
adaptive changes in the myocardium contributing to both improved insulin 
sensitivity and metabolic health of the organ. A previous study has revealed that 
increased oxidative capacity and capillary density were observed in skeletal muscle 
in response to aerobic exercise [77]. Similarly, insulin sensitivity in adipose tissue is 
increased within 72-hours after completion of a 6-week exercise intervention [78]. 
Likewise, calcium homeostasis has a major role in the excitation contracting-cou-
pling process of the heart and ET has been shown to improve significantly cardiac 
myocytes contractility during diabetes due to an improvement of Ca2+ homeostasis. 
It was reported that ET can also prevent the development of SCD and the dysregula-
tion of SR protein content in an inducible animal model of T2DM [80]. It is now 
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well established that most athletes have a low resting heart rate (brady-arrhyth-
mias), typical of 40–60 beats per minute due to high vagal tone in the heart.
14. Treatment of sudden cardiac death
Therapy of SCD includes non-pharmacological and pharmacological 
interventions. There are a number of therapeutic options, but the main non- 
pharmacological therapy is the use of defibrillators [5, 6, 81–83]. However, there 
must be more community-based public access to defibrillation programs in order 
to save the lives of those patients who are more impacted. Other factors include 
screening of family members who are susceptible to arrhythmias and SCD and 
this in turn will help with early diagnosis and also and managing the arrhythmias. 
Generally, potential patients have to change their lifestyle habits by reducing their 
stress level, avoid smoking and drinking alcohol, eat a heart healthy Mediterranean 
diet and participate in moderate daily exercise. Moreover, potential patients should 
also education themselves about the signs and symptoms of SCD and how to obtain 
early treatment. Likewise, public health services globally should introduce health 
education on SCD to students, workers, patients and others. In terms of pharma-
cological intervention, SCD patients are treated mainly with beta blockers, ACE 
inhibitors, anti-arrhythmic drugs and in some cases, amiodarone. These drugs exert 
their beneficial effects via different cellular and subcellular mechanisms by slowing 
the rate and force of contraction of the myocardium [81].
It is now the general consensus that the implantable cardioverter-defibrillators 
(ICD) which was first implanted in patients in the 1980 is the mainstay life-saving 
and cost-effective clinical device in treating cardiac patients with dangerous 
abnormal life-threatening arrhythmias and also in the treatment of resuscitated 
survivors of sudden cardiac arrest substantially and with increased life expectancy 
compared to pharmacological therapies, including amiodarone [82]. ICD is also 
employed for primary prevention in high-risk patients, and in biventricular pacing 
of patients at high risk for arrhythmic events. More recent studies have reported 
that subcutaneous implantable cardioverter defibrillator (SIDC) is both safe and 
effective instead of the ICD as an alternative to prevent SCD [83]. The indica-
tions and use of the ICDs and SIDCs will continue to grow, resulting in increasing 
discussions about costs compared to other forms of therapy and the necessity of 
better selection of ICD/SIDC recipients depending on age, duration of the illness, 
risks and others [84]. Improvement of results of resuscitation from out-of-hospital 
cardiac arrest remains an important challenge. Both better methods to recognize 
asymptomatic patients at risk including genetic screening and development of new 
technologies to shorten the time interval between cardiac arrest and the resuscita-
tion effort are urgently needed [84]. Further information can be found in the 2017 
AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias 
and prevention of sudden cardiac death [85].
15. Conclusion
Figure 5 summarizes the major events leading to SCD during the development 
of DM as a result of the various risk factors. It is proposed that during elevated or 
uncontrolled level of blood glucose (hyperglycemia) due to DM, the body produces 
a number of endogenous pathological compounds called oxidants, which are 
classified either as reactive oxygen species (ROS such as 2O−, H2O2, and others) or 
RCS. One particular RCS is methylglyoxal (MGO), which is elevated to toxic levels. 
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This is due to increased synthesis and a decrease in the activity of glyoxylase-1, 
the enzyme that metabolizes MGO in the different organs of the body [55]. In the 
heart, MGO exerts a deleterious effect resulting in death of some cells (apoptosis), 
enlargement and disarray of the structure of cardiac muscles and other tissues 
which are associated with an elevation of transforming growth factor beta-1 
(TGF-beta-1), which in turn elicits hypertrophy of the heart and infiltration of 
fibrosis [86]. These processes lead to a derangement in cellular calcium homeostasis 
(elevated diastolic calcium) followed by DC. The resulting effect is remodeling 
of the heart so that it can maintain its function to pump blood around the body 
but not at physiological level [87]. Thus, the pathogenesis of diabetic cardiomy-
opathy in diabetic patients is multifactorial and complex, eventually leading to an 
energetically compromised heart with reduced working capacity or heart failure, 
arrhythmias, and SCD. Luckily, patients now have a number of therapies including 
non-pharmacological and pharmacological interventions to treat SCD.
Figure 5. 
A flow diagram illustrating the events, starting from the risk factors that lead to sudden cardiac death in 
diabetes mellitus. ROS, reactive oxygen species; MGO, methylglyoxal; TGF-beta, transforming growth factor-
beta; SCD, sudden cardiac death.
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